OncoMatch/Clinical Trials/NCT07208773
A Study of YL201 and Ivonescimab (AK112) in Advanced Solid Tumors
Is NCT07208773 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies multiple treatments including YL201 and Ivonescimab for advanced solid tumors.
Treatment: YL201 · Ivonescimab — This study was designed to evaluate the efficacy and safety of YL201 in combination with Ivonescimab (AK112) in subjects with solid tumor.
Check if I qualifyExtracted eligibility criteria
Cancer type
Tumor Agnostic
Small Cell Lung Cancer
Biomarker criteria
Required: EGFR mutation
Disease stage
Required: Stage IV
Metastatic disease required
Phase 1: Advanced Solid tumors. Phase 2: Extensive-stage SCLC, Non-AGA NSCLC, EGFR mutation NSCLC.
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: B7-H3-targeted therapy
previous treatment with drugs targeting B7-H3 (including antibodies, ADCs, CAR-T, and other drugs)
Cannot have received: topoisomerase I inhibitor
previous treatment with topoisomerase I inhibitors or ADCs containing topoisomerase I inhibitors
Lab requirements
Blood counts
functions of body organs and bone marrow meet the requirements
Kidney function
functions of body organs and bone marrow meet the requirements
Liver function
functions of body organs and bone marrow meet the requirements
Within 7 days before the first dose, the functions of body organs and bone marrow meet the requirements.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify